ABSTRACT Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment with this drug before allo-SCT will increase the

toxicity of the preparative regimen or otherwise affect the results of the transplant. We report the outcome of 17 patients with MDS with a median age of 55.5 years (range, 36–66 years) who

underwent an allo-SCT (12 siblings, 5 unrelated) after prior therapy with decitabine. Preparative regimens consisted of fludarabine in combination with BU (_n_=8) or melphalan (_n_=9). The

source of stem cells was marrow in four patients and peripheral blood (PB) in 13 patients. Thirteen patients were in CR within 100 days of transplant. With a median follow-up of 12 months

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS REDUCED INTENSITY VERSUS MYELOABLATIVE CONDITIONING FOR MDS:

LONG-TERM RESULTS OF AN EBMT PHASE III STUDY (RICMAC) Article Open access 25 April 2024 THIOTEPA–FLUDARABINE–TREOSULFAN CONDITIONING FOR 2ND ALLOGENEIC HCT FROM AN ALTERNATIVE UNRELATED

DONOR FOR PATIENTS WITH AML: A PROSPECTIVE MULTICENTER PHASE II TRIAL Article Open access 18 August 2022 ORAL DECITABINE CEDAZURIDINE WITH AND WITHOUT VENETOCLAX IN HIGHER-RISK

MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA: A PROPENSITY SCORE–MATCHED STUDY Article Open access 31 March 2025 REFERENCES * Schiffer CA . Clinical issues in the management

of patients with myelodysplasia. In: Gerwitz AM, Winter JN, Zuckerman K (eds). _Hematology, Am Soc Hematol Educ Program_, 2006, pp 205–210. Article  Google Scholar  * Silverman LR, Demakos

EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R _et al_. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and

leukemia group B. _J Clin Oncol_ 2002; 20: 2429–2440. Article  CAS  Google Scholar  * Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J _et al_. Decitabine improves

patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. _Cancer_ 2006; 106: 1794–1803. Article  CAS  Google Scholar  * List A, Dewald G, Bennett J,

Giagounidis A, Raza A, Feldman E _et al_. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. _N Engl J Med_ 2006; 355: 1456–1465. Article  CAS  Google Scholar  *

Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. _N Engl J Med_ 2003; 349: 2042–2054. Article  CAS  Google Scholar  * Issa JP . CpG island

methylator phenotype in cancer. _Nat Rev Cancer_ 2004; 4: 988–993. Article  CAS  Google Scholar  * Issa JP . Optimizing therapy with methylation inhibitors in myelodysplastic syndromes:dose,

duration, and patient selection. _Nat Clin Pract Oncol_ 2005; 2: 24–29. Article  Google Scholar  * Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP . Methylation profiling in

acute myeloid leukemia. _Blood_ 2001; 97: 2823–2829. Article  CAS  Google Scholar  * Pinto A, Zagonel V . 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute

myeloid leukemias and myelodysplastic syndromes: past, present and future trends. _Leukemia_ 1993; 7: 51–60. PubMed  Google Scholar  * Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R .

Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. _Lancet_ 1984; 2: 867–868. Article  CAS  Google Scholar  * Pinto A,

Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A _et al_. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.

_Bone Marrow Transplant_ 1989; 4: 28–32. PubMed  Google Scholar  * Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J _et al_. Results of a randomized study of 3

schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. _Blood_ 2007; 109: 52–57. Article  CAS  Google Scholar  * Swerdlow SH, Campo E,

Harris NL, Jaffe ES, Pileri SA, Atein H _et al_. (eds). _World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues_, 4th edn. International Agency for

Research on Cancer (IARC), 2008, 439pp. Google Scholar  * Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C _et al_. A decision analysis of allogeneic bone marrow transplantation

for the myelodysplasia syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. _Blood_ 2004; 104: 579–585. Article  CAS  Google Scholar  * Ambs

A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB . Overview of the SEER—medicare health outcomes survey linked dataset. _Health Care Financ Rev_ 2008 Summer; 29: 5–21. PubMed 

PubMed Central  Google Scholar  * de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N _et al_. Haematopoietic stem cell transplantation for patients with myelo-dysplastic

syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). _Br J Haematol_

2000; 110: 620–630. Article  CAS  Google Scholar  * Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG _et al_. Hematopoietic cell transplantation (HCT)-specific comorbidities

index: a new tool for risk assessment before allogeneic HCT. _Blood_ 2005; 106: 2912–2919. Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA L De Padua Silva, M de Lima, P Kebriaei, S Giralt & R

Champlin * Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA L De Padua Silva, H Kantarjian, S Faderl, J Davisson, G Garcia-Manero, J-P Issa & F

Ravandi Authors * L De Padua Silva View author publications You can also search for this author inPubMed Google Scholar * M de Lima View author publications You can also search for this

author inPubMed Google Scholar * H Kantarjian View author publications You can also search for this author inPubMed Google Scholar * S Faderl View author publications You can also search for

this author inPubMed Google Scholar * P Kebriaei View author publications You can also search for this author inPubMed Google Scholar * S Giralt View author publications You can also search

for this author inPubMed Google Scholar * J Davisson View author publications You can also search for this author inPubMed Google Scholar * G Garcia-Manero View author publications You can

also search for this author inPubMed Google Scholar * R Champlin View author publications You can also search for this author inPubMed Google Scholar * J-P Issa View author publications You

can also search for this author inPubMed Google Scholar * F Ravandi View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence

to M de Lima. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE De Padua Silva, L., de Lima, M., Kantarjian, H. _et al._ Feasibility of allo-SCT after

hypomethylating therapy with decitabine for myelodysplastic syndrome. _Bone Marrow Transplant_ 43, 839–843 (2009). https://doi.org/10.1038/bmt.2008.400 Download citation * Received: 08 July

2008 * Revised: 15 October 2008 * Accepted: 17 October 2008 * Published: 19 January 2009 * Issue Date: June 2009 * DOI: https://doi.org/10.1038/bmt.2008.400 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative KEYWORDS * myelodysplastic syndrome * decitabine * allo-SCT